Preparations of the thiazolidinedione family’s activators of PPARγ improved adiponectin levels while possessing a neutral effect on leptin levels in several studies including participants with NAFLD, nonalcoholic steatohepatitis, and type 2 diabetes; however, their clinical use was limited by long-term side effects such as increased risk of myocardial infarction [148]. The gene discussed is LEP; the disease is type 2 diabetes mellitus.